Evidence map›Paper›PMID 33919991›Full record

ArticleNutrients2021

L-Carnitine Tartrate Downregulates the ACE2 Receptor and Limits SARS-CoV-2 Infection.

Aouatef Bellamine, Tram N Q Pham, Jaspreet Jain, Jacob Wilson, Kazim Sahin, Frederic Dallaire, Nabil G Seidah, Shane Durkee, Katarina Radošević, Éric A Cohen

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Can l-carnitine reduce post-COVID-19 fatigue?Annals of medicine and surgery (2012) · 2022
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Aouatef BellamineLonza Consumer Health, Morristown, NJ 07960, USA.
Tram N Q PhamInstitut de Recherche Clinique de Montreal, Montreal, QC H2W1R7, Canada.
Jaspreet JainInstitut de Recherche Clinique de Montreal, Montreal, QC H2W1R7, Canada.
Jacob WilsonApplied Science and Performance Institute, Tampa, FL 33607, USA.
Kazim SahinDepartment of Animal Nutrition, Faculty of Veterinary Medicine, Firat University, Elazig 23119, Turkey.ORCID 0000-0001-9542-5244
Frederic DallaireInstitut de Recherche Clinique de Montreal, Montreal, QC H2W1R7, Canada.
Nabil G SeidahInstitut de Recherche Clinique de Montreal, Montreal, QC H2W1R7, Canada.ORCID 0000-0001-6503-9342
Shane DurkeeLonza Consumer Health, Morristown, NJ 07960, USA.
Katarina RadoševićBiologics R&D, Lonza Pharma & Biotech, 4057 Basel, Switzerland.
Éric A CohenInstitut de Recherche Clinique de Montreal, Montreal, QC H2W1R7, Canada.ORCID 0000-0003-1269-3791
Montreal Clinical Research Institute · CALonza (United States) · USFırat University · TRLonza (Switzerland) · CH

Funding

CIHR Foundation grant 148363
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for one of the worst pandemics in modern history. Several prevention and treatment strategies have been designed and evaluated in recent months either through the repurposing of existing treatments or the development of new drugs and vaccines. In this study, we show that L-carnitine tartrate supplementation in humans and rodents led to significant decreases of key host dependency factors, notably angiotensin-converting enzyme 2 (ACE2), transmembrane protease serine 2 (TMPRSS2), and Furin, which are responsible for viral attachment, viral spike S-protein cleavage, and priming for viral fusion and entry. Interestingly, pre-treatment of Calu-3, human lung epithelial cells, with L-carnitine tartrate led to a significant and dose-dependent inhibition of the infection by SARS-CoV-2. Infection inhibition coincided with a significant decrease in ACE2 mRNA expression levels. These data suggest that L-carnitine tartrate should be tested with appropriate trials in humans for the possibility to limit SARS-CoV-2 infection.

Indexed as

COVID-19 Drug TreatmentAdultAgedAngiotensin-Converting Enzyme 2AnimalsCarnitineCell LineCell SurvivalCOVID-19FemaleFurinHumansInflammationMaleMiddle AgedRatsAngiotensin-Converting Enzyme 2CarnitineFurinSerine EndopeptidasesTartratesTMPRSS2 protein, humanACE-2COVID-19exerciseFurininflammationL-carnitineSARS-CoV-2TMPRSS2

Identifiers

PMID33919991
PMCPMC8071056
OpenAlexW3152913235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.